{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T14:47:10Z","timestamp":1787237230770,"version":"build-2736575974"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"vor","delay-in-days":688,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T00:00:00Z","timestamp":1701043200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Guideline-directed medical therapy (GDMT) has improved outcomes in patients with heart failure, including the use of renin\u2013angiotensin\u2013aldosterone system inhibitors, which can hinder the excretion of potassium, resulting in hyperkalaemia. New potassium binders (NPBs) can prevent this adverse effect; however, the efficacy and safety of NPB for this indication have not been fully established. We conducted a systematic review and meta-analysis synthesizing randomized controlled trials (RCTs), which were retrieved by systematically searching PubMed, Web of Science, Scopus, and Cochrane through 26 April 2023. The risk of bias assessment was conducted, following Cochrane's updated Risk of Bias 2 assessment tool. We used the fixed-effects model to pool dichotomous data using risk ratio (RR) and continuous data using mean difference (MD), with a 95% confidence interval (CI) (PROSPERO ID: CRD42023426113). We included six RCTs with a total of 1432 patients. NPB was significantly associated with successful mineralocorticoid receptor antagonist (MRA) optimization [RR: 1.13 with 95% CI (1.02\u20131.25), P = 0.02], decreased patients with MRA at less than the target dose [RR: 0.72 with 95% CI (0.57\u20130.90), P = 0.004], and decreased hyperkalaemic episodes [RR: 0.42 with 95% CI (0.24\u20130.72), P = 0.002]. However, there was no difference between NPB and placebo regarding angiotensin-converting enzyme inhibitor (ACEi)\/angiotensin receptor blocker (ARB)\/angiotensin receptor\/neprilysin inhibitor (ANRi) optimization [RR: 1.02 with 95% CI (0.89\u20131.17), P = 0.76] and serum potassium change [MD: \u22120.31 with 95% CI (\u22120.61 to 0.00), P = 0.05], with an acceptable safety profile except for the increased incidence of hypokalaemia with NPB [RR: 1.57 with 95% CI (1.12\u20132.21), P = 0.009]. NPB has been shown to improve GDMT outcomes by enhancing MRA optimization and reducing hyperkalaemic episodes. However, there are limited data on the effects of NPB on ACEi\/ARB\/ANRi optimization. Future RCTs should investigate ACEi\/ARB\/ANRi optimization and conduct head-to-head comparisons of NPB (patiromer and sodium zirconium cyclosilicate).<\/jats:p>","DOI":"10.1002\/ehf2.14588","type":"journal-article","created":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T22:43:45Z","timestamp":1701125025000},"page":"28-43","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["The Efficacy and Safety of New Potassium Binders on Renin\u2013Angiotensin\u2013Aldosterone System Inhibitor Optimization in Heart Failure Patients: A Systematic Review and Meta-Analysis"],"prefix":"10.1093","volume":"11","author":[{"given":"Mohamed","family":"Abuelazm","sequence":"first","affiliation":[{"name":"Faculty of Medicine, Tanta University , Tanta ,","place":["Egypt"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amr","family":"Badr","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Banha Teaching Hospital , Banha ,","place":["Egypt"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4261-0638","authenticated-orcid":false,"given":"Mustafa","family":"Turkmani","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, McLaren Health Care , Oakland, MI ,","place":["USA"]},{"name":"Department of Internal Medicine, Michigan State University , East Lansing, MI ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mostafa Atef","family":"Amin","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Cairo University , Cairo ,","place":["Egypt"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed Mazen","family":"Amin","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Mansoura University , Mansoura ,","place":["Egypt"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aya","family":"Aboutaleb","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Zagazig University , Zagazig ,","place":["Egypt"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Gowaily","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Tanta University , Tanta ,","place":["Egypt"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youssef","family":"Soliman","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Assiut University , Asyut ,","place":["Egypt"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2919-6196","authenticated-orcid":false,"given":"Basel","family":"Abdelazeem","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Michigan State University , East Lansing, MI ,","place":["USA"]},{"name":"Department of Cardiology, West Virginia University , Morgantown, WV ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,11,27]]},"reference":[{"key":"2026012113074277500_ehf214588-bib-0001","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/j.jacc.2017.04.025","article-title":"2017 ACC\/AHA\/HFSA focused update of the 2013 ACCF\/AHA guideline for the management of heart failure: A report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America","volume":"70","author":"Yancy","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2026012113074277500_ehf214588-bib-0002","doi-asserted-by":"publisher","first-page":"7","DOI":"10.15420\/cfr.2016:25:2","article-title":"Global public health burden of heart failure","volume":"03","author":"Savarese","year":"2017","journal-title":"Card Fail Rev"},{"key":"2026012113074277500_ehf214588-bib-0003","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1001\/jamacardio.2017.2198","article-title":"Efficacy and safety of spironolactone in acute heart failure: The ATHENA-HF randomized clinical trial","volume":"2","author":"Butler","year":"2017","journal-title":"JAMA Cardiol"},{"key":"2026012113074277500_ehf214588-bib-0004","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1002\/ejhf.402","article-title":"Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors","volume":"17","author":"Pitt","year":"2015","journal-title":"Eur J Heart Fail [Internet]"},{"key":"2026012113074277500_ehf214588-bib-0005","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1093\/eurheartj\/ehq502","article-title":"Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial","volume":"32","author":"Pitt","year":"2011","journal-title":"Eur Heart J"},{"key":"2026012113074277500_ehf214588-bib-0006","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1002\/ejhf.1860","article-title":"Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): Results in the pre-specified subgroup with heart failure","volume":"22","author":"Rossignol","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012113074277500_ehf214588-bib-0007","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1002\/ehf2.14268","article-title":"Potassium reduction with sodium zirconium cyclosilicate in patients with heart failure","volume":"2022","author":"Tardif","year":"2022","journal-title":"ESC Hear Fail"},{"key":"2026012113074277500_ehf214588-bib-0008","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1002\/ejhf.300","article-title":"Maintenance of serum potassium with sodium zirconium cyclosilicate (ZS-9) in heart failure patients: Results from a phase 3 randomized, double-blind, placebo-controlled trial","volume":"17","author":"Anker","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"2026012113074277500_ehf214588-bib-0009","doi-asserted-by":"publisher","first-page":"4362","DOI":"10.1093\/eurheartj\/ehac401","article-title":"Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: The DIAMOND trial","volume":"43","author":"Butler","year":"2022","journal-title":"Eur Heart J [Internet]"},{"key":"2026012113074277500_ehf214588-bib-0010","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-021-01626-4","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","author":"Page","year":"2021","journal-title":"BMJ [Internet]"},{"key":"2026012113074277500_ehf214588-bib-0011","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/9781119536604","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins","year":"2019"},{"key":"2026012113074277500_ehf214588-bib-0012","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: A revised tool for assessing risk of bias in randomised trials","author":"Sterne","year":"2019","journal-title":"BMJ [Internet]"},{"key":"2026012113074277500_ehf214588-bib-0013","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1136\/bmj.39490.551019.BE","article-title":"Rating quality of evidence and strength of recommendations: What is \u201cquality of evidence\u201d and why is it important to clinicians?","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ Br Med J [Internet]"},{"key":"2026012113074277500_ehf214588-bib-0014","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: An emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ Br Med J [Internet]"},{"key":"2026012113074277500_ehf214588-bib-0015","volume-title":"RevMan|Cochrane Training [Internet]"},{"key":"2026012113074277500_ehf214588-bib-0016","doi-asserted-by":"publisher","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","year":"2022","DOI":"10.4103\/ijdr.ijdr_810_21"},{"key":"2026012113074277500_ehf214588-bib-0017","doi-asserted-by":"publisher","volume-title":"TSA\u2014ctu.dk [Internet]","year":"2021","DOI":"10.12688\/f1000research.73248.2"},{"key":"2026012113074277500_ehf214588-bib-0018","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/kisup.2012.46","article-title":"Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease","volume":"2","author":"Becker","year":"2012","journal-title":"Kidney Int Suppl"},{"key":"2026012113074277500_ehf214588-bib-0019","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"2026012113074277500_ehf214588-bib-0020","first-page":"565","article-title":"2021 update to the 2017 ACC expert consensus decision pathway for optimization of heart failure treatment: Answers to 10 pivotal issues about heart failure with reduced ejection fraction: A report of the American College of Cardiology Solution Set Oversight Committee","volume":"75","author":"Steiner","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2026012113074277500_ehf214588-bib-0021","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1002\/ejhf.2024","article-title":"Effects of hyperkalaemia and non-adherence to renin\u2013angiotensin\u2013aldosterone system inhibitor therapy in patients with heart failure in Italy: A propensity-matched study","volume":"22","author":"Volterrani","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012113074277500_ehf214588-bib-0022","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1002\/ejhf.2418","article-title":"Temporal trends in initiation of mineralocorticoid receptor antagonists and risk of subsequent withdrawal in patients with heart failure: A nationwide study in Denmark from 2003\u20132017","volume":"24","author":"Zahir","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026012113074277500_ehf214588-bib-0023","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1002\/ejhf.2287","article-title":"Stopping mineralocorticoid receptor antagonists after hyperkalaemia: Trial emulation in data from routine care","volume":"23","author":"Trevisan","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012113074277500_ehf214588-bib-0024","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1002\/ejhf.2271","article-title":"Heart failure drug titration, discontinuation, mortality and heart failure hospitalization risk: A multinational observational study (US, UK and Sweden)","volume":"23","author":"Savarese","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012113074277500_ehf214588-bib-0025","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1002\/ejhf.1199","article-title":"Incidence, predictors and clinical management of hyperkalaemia in new users of mineralocorticoid receptor antagonists","volume":"20","author":"Trevisan","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012113074277500_ehf214588-bib-0026","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1002\/ejhf.1182","article-title":"Factors associated with underuse of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: An analysis of 11 215 patients from the Swedish Heart Failure Registry","volume":"20","author":"Savarese","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012113074277500_ehf214588-bib-0027","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1002\/ejhf.1793","article-title":"Unravelling the interplay between hyperkalaemia, renin\u2013angiotensin\u2013aldosterone inhibitor use and clinical outcomes. Data from 9222 chronic heart failure patients of the ESC-HFA-EORP Heart Failure Long-Term Registry","volume":"22","author":"Rossignol","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012113074277500_ehf214588-bib-0028","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1007\/s10741-020-10069-3","article-title":"Management of RAASi-associated hyperkalemia in patients with cardiovascular disease","volume":"26","author":"Silva-Cardoso","year":"2021","journal-title":"Heart Fail Rev"},{"key":"2026012113074277500_ehf214588-bib-0029","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10071721","article-title":"Optimizing therapies in heart failure: The role of potassium binders","volume":"10","author":"Scicchitano","year":"2022","journal-title":"Biomedicine"},{"key":"2026012113074277500_ehf214588-bib-0030","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.118.009429","article-title":"Hyperkalemia in heart failure: Probably not O\u201cK\u201d","volume":"7","author":"Fudim","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"2026012113074277500_ehf214588-bib-0031","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1002\/ehf2.14285","article-title":"Serum potassium level and mineralocorticoid receptor antagonist dose in a large cohort of chronic heart failure patients","volume":"10","author":"Clephas","year":"2023","journal-title":"ESC Hear Fail"},{"key":"2026012113074277500_ehf214588-bib-0032","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s10741-020-10039-9","article-title":"Serum potassium and heart failure: Association, causation, and clinical implications","volume":"26","author":"Sfairopoulos","year":"2021","journal-title":"Heart Fail Rev"},{"key":"2026012113074277500_ehf214588-bib-0033","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1002\/ejhf.1757","article-title":"Association between potassium level and outcomes in heart failure with reduced ejection fraction: A cohort study from the Swedish Heart Failure Registry","volume":"22","author":"Cooper","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012113074277500_ehf214588-bib-0034","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1177\/1074248416629549","article-title":"Mechanism of action and pharmacology of patiromer, a nonabsorbed cross-linked polymer that lowers serum potassium concentration in patients with hyperkalemia","volume":"21","author":"Li","year":"2016","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"2026012113074277500_ehf214588-bib-0035","doi-asserted-by":"publisher","DOI":"10.1016\/j.curtheres.2021.100635","article-title":"Patiromer and sodium zirconium cyclosilicate in treatment of hyperkalemia: A systematic review and meta-analysis","volume":"95","author":"Shrestha","year":"2021","journal-title":"Curr Ther Res\u2014Clin Exp"},{"key":"2026012113074277500_ehf214588-bib-0036","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.jchf.2018.10.003","article-title":"Incidence, predictors, and outcome associations of dyskalemia in heart failure with preserved, mid-range, and reduced ejection fraction","volume":"7","author":"Savarese","year":"2019","journal-title":"JACC Hear Fail"},{"key":"2026012113074277500_ehf214588-bib-0037","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10235483","article-title":"Optimization of RAASi therapy with new potassium binders for patients with heart failure and hyperkalemia: Rapid review and meta-analysis","volume":"10","author":"Montagnani","year":"2021","journal-title":"J Clin Med"},{"key":"2026012113074277500_ehf214588-bib-0038","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1007\/s00392-023-02215-2","article-title":"Safety and efficacy of new potassium binders on hyperkalemia management in patients with heart failure: A systematic review and meta-analysis of randomized controlled trials","volume":"112","author":"Carvalho","year":"2023","journal-title":"Clin Res Cardiol"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/11\/1\/28\/64508958\/eschf_11_1_28.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/11\/1\/28\/64508958\/eschf_11_1_28.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T18:08:15Z","timestamp":1769018895000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/11\/1\/28\/8268237"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,27]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,11,27]]},"published-print":{"date-parts":[[2024,2,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.14588","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,2]]},"published":{"date-parts":[[2023,11,27]]},"assertion":[{"value":"2023-07-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-29","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-11-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}